Chief Scientific Officer
He has 20 years’ experience in drug discovery and development and has successfully led a growing portfolio of antibody, antibody fragment and recombinant protein therapeutics from concept to clinical development. He joined F-star from GlaxoSmithKline (GSK) where he was Vice President, Head of Biopharmaceutical Research. He played a key leadership role, as Head of Research, in the success of building Domantis until the company was acquired by GSK in 2007. He is an Honorary Doctor of Science from Hertfordshire University and sits on the BBSRC Council. He holds a PhD in Biochemistry from Dundee University, UK.
Recombinant protein therapeutics.